Ong Voon, Hough Grayson, Schlosser Michael, Bartizal Ken, Balkovec James M, James Kenneth D, Krishnan B Radha
Cidara Therapeutics, Inc., San Diego, California, USA
Cidara Therapeutics, Inc., San Diego, California, USA.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6872-6879. doi: 10.1128/AAC.00701-16. Print 2016 Nov.
Fungal infections pose a significant public health burden with high morbidity and mortality. CD101 is a novel echinocandin under development for the treatment and prevention of systemic Candida infections. Preclinical studies were conducted to evaluate the metabolic stability, plasma protein binding, pharmacokinetics, toxicity, and efficacy of CD101 at various dose levels. CD101 was stable to biotransformation in rat, monkey, and human liver microsomes and rat, monkey, dog, and human hepatocytes. In vitro studies suggest minimal interaction with recombinant cytochrome P450 enzymes (50% inhibitory concentrations [ICs] of >10 μM). Similar to anidulafungin, CD101 bound avidly (>98%) to human, mouse, rat, and primate plasma proteins. In a 2-week repeat-dose comparison study, CD101 was well tolerated in rats (no effects on body weight, hematology, coagulation, or urinalysis). In contrast, administration of anidulafungin (at comparable exposure levels) resulted in reduced body weight, decreases in red blood cell, hemoglobin, hematocrit, mean cell volume, mean corpuscular hemoglobin, platelet, and reticulocyte counts, increases in neutrophil and eosinophil counts, polychromasia, and decreased activated partial thromboplastin time. Elevated plasma transaminases, total bilirubin, cholesterol, and globulin, dark and enlarged spleens, and single-cell hepatocyte necrosis were also observed for anidulafungin but not CD101. Hepatotoxicity may be due to the inherent chemical lability of anidulafungin generating potentially reactive intermediates. A glutathione trapping experiment confirmed the formation of a reactive species from anidulafungin, whereas CD101 did not exhibit instability or reactive intermediates. CD101 showed antifungal activity against Candida and Aspergillus infections in neutropenic mice. These preclinical studies demonstrated that CD101 is chemically and metabolically stable, well tolerated with no hepatotoxicity, and efficacious as an antifungal agent.
真菌感染造成了重大的公共卫生负担,发病率和死亡率都很高。CD101是一种正在开发的新型棘白菌素,用于治疗和预防系统性念珠菌感染。进行了临床前研究,以评估不同剂量水平下CD101的代谢稳定性、血浆蛋白结合率、药代动力学、毒性和疗效。CD101在大鼠、猴子和人肝微粒体以及大鼠、猴子、狗和人肝细胞中对生物转化稳定。体外研究表明,与重组细胞色素P450酶的相互作用极小(50%抑制浓度[IC]>10μM)。与阿尼芬净相似,CD101与人类、小鼠、大鼠和灵长类动物的血浆蛋白紧密结合(>98%)。在一项为期2周的重复给药比较研究中,大鼠对CD101耐受性良好(对体重、血液学、凝血或尿液分析无影响)。相比之下,给予阿尼芬净(在相当的暴露水平下)导致体重减轻、红细胞、血红蛋白、血细胞比容、平均细胞体积、平均红细胞血红蛋白、血小板和网织红细胞计数减少;中性粒细胞和嗜酸性粒细胞计数增加、出现嗜多色性红细胞,活化部分凝血活酶时间缩短。还观察到阿尼芬净组血浆转氨酶、总胆红素、胆固醇和球蛋白升高,脾脏变黑肿大,以及单细胞肝细胞坏死,但CD101组未出现这些情况。肝毒性可能是由于阿尼芬净固有的化学不稳定性产生了潜在的反应性中间体。谷胱甘肽捕获实验证实阿尼芬净形成了一种反应性物质,而CD101未表现出不稳定性或反应性中间体。CD101对中性粒细胞减少小鼠的念珠菌和曲霉菌感染显示出抗真菌活性。这些临床前研究表明,CD101在化学和代谢上稳定,耐受性良好,无肝毒性,作为抗真菌剂有效。